Clinical Trials Logo

Alzheimers Disease clinical trials

View clinical trials related to Alzheimers Disease.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05256134 Terminated - Alzheimers Disease Clinical Trials

A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)

SKYLINE
Start date: April 19, 2022
Phase: Phase 3
Study type: Interventional

A study to evaluate the efficacy and safety of gantenerumab in amyloid-positive, cognitively unimpaired participants at risk for or at the earliest stages of AD. The planned number of participants for this study is approximately 1200 participants randomized in a 1:1 ratio to receive either gantenerumab or placebo (600 participants randomized to gantenerumab and 600 participants randomized to placebo).

NCT ID: NCT05097131 Terminated - Alzheimers Disease Clinical Trials

An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US

Start date: November 18, 2021
Phase:
Study type: Observational

This is a prospective, single-arm, multicenter, non-interventional study of aducanumab-avwa as prescribed in the post-marketing setting in the US. Investigators will be prescribing aducanumab-avwa and participants will be treated according to the standard of care (SoC). Participants will be followed up to 5 years after enrollment and data will be collected at routine visits every 6 to 12 months.

NCT ID: NCT03131453 Terminated - Alzheimers Disease Clinical Trials

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

GS2
Start date: August 3, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.

NCT ID: NCT02565511 Terminated - Alzheimers Disease Clinical Trials

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

GS1
Start date: November 30, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.

NCT ID: NCT01733355 Terminated - Alzheimers Disease Clinical Trials

A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807

Start date: July 2012
Phase: Phase 0
Study type: Interventional

[F-18]T807 is being developed as a diagnostic radiopharmaceutical for PET imaging of the human brain.

NCT ID: NCT01723488 Terminated - Alzheimers Disease Clinical Trials

A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808

T808
Start date: July 2012
Phase: Phase 0
Study type: Interventional

[F-18]T808 is being developed as a diagnostic radiopharmaceutical for PET imaging of the human brain.